SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

  1. Redin, E.
  2. Garmendia, I.
  3. Lozano, T.
  4. Serrano, D.
  5. Senent, Y.
  6. Redrado, M.
  7. Villalba, M.
  8. De Andrea, C.E.
  9. Exposito, F.
  10. Ajona, D.
  11. Ortiz-Espinosa, S.
  12. Remirez, A.
  13. Bertolo, C.
  14. Sainz, C.
  15. Garcia-Pedrero, J.
  16. Pio, R.
  17. Lasarte, J.
  18. Agorreta, J.
  19. Montuenga, L.M.
  20. Calvo, A.
Revista:
Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426

Any de publicació: 2021

Volum: 9

Número: 3

Tipus: Article

DOI: 10.1136/JITC-2020-001496 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus